ST Pharm Signs Supply Contract for Oligonucleotide Therapeutic APIs with US Biotech Company
Worth Approximately 82.5 Billion Won
ST Pharm announced on January 23 that it has signed a contract worth 56 million dollars (approximately 82.5 billion won) to supply active pharmaceutical ingredients (APIs) for oligonucleotide therapeutics to a global biotech company based in the United States.
According to ST Pharm, the name of the client company and the product will not be disclosed due to confidentiality agreements. The contract period runs from January 22 to December 18 of this year.
The API covered by this supply contract is a treatment for severe hypertriglyceridemia. It will be used in a new drug scheduled for commercialization.
Last year, ST Pharm completed the construction of its second oligonucleotide production building and will begin full-scale operations in the second half of the year. According to the company, this facility is equipped with process stability and impurity minimization systems, enabling consistent quality from clinical to commercial production.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A representative from ST Pharm stated, "We are strengthening our capability to stably supply oligonucleotide therapeutic APIs through an integrated platform that encompasses technology, regulatory, and supply chain aspects. From the early development stage to process, analysis, and change approval, we provide a variety of services tailored to client needs."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.